Real-world evidence (RWE) generates largest study population in patients with aNSCLC
- Patients EPRs were utilised to generate RWE on treatment patterns and clinical outcomes for patients with aNSCLC in the UK
- 1003 patients who started a first-line treatment for aNSCLC were included from nine UK hospitals
- The evidence highlighted the need for improved treatment options for tumours lacking targetable mutations
Click here to read more
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.